The Trump administration is set to announce potential links between the use of Tylenol (acetaminophen) during pregnancy and autism, according to a report by The Washington Post. Federal health officials are expected to advise against using Tylenol in early pregnancy unless necessary for fever management. Additionally, they will introduce leucovorin, a form of folate, as a possible treatment for autism.
President Donald Trump mentioned that this announcement is significant, emphasizing its importance during remarks at an event hosted by the American Cornerstone Institute. Health and Human Services Secretary Robert F. Kennedy Jr. is reportedly preparing a report that connects acetaminophen use during pregnancy with autism, a claim that has raised concerns in the medical community.
In response, Kenvue, the maker of Tylenol, has stated that extensive research does not support any credible link between acetaminophen and autism, expressing concern over the implications this announcement could have for expectant mothers. The company highlighted that leading medical professionals and health regulators endorse its safety when used as directed. Kenvue has also added information to its website addressing media coverage surrounding this issue, reiterating that there is no proven connection between Tylenol and autism.
The Food and Drug Administration, along with major medical organizations, has maintained that acetaminophen is safe for use during pregnancy when consulted with a healthcare provider. Kennedy, who has focused on autism as a priority for his department, has previously made controversial statements regarding the condition and its causes.
As the announcement approaches, the implications for public health and the pharmaceutical industry remain to be seen, particularly given the mixed messages from regulatory bodies and Kenvue.